Keros Therapeutics, Inc. - KROS STOCK NEWS

Keros Therapeutics, Inc. (KROS) announced promising preclinical results for RKER-012, a novel treatment for pulmonary arterial hypertension (PAH). The findings, presented at the American Heart Association 2022 Scientific Sessions, show that RKER-012 improved cardiac and pulmonary function in a rat model of PAH. The treatment significantly reduced inflammatory and fibrotic markers, indicating potential for treating not just PAH but other inflammatory diseases. KER-012's development targets crucial pathways involved in fibrosis and cardiac hypertrophy.

Keros Therapeutics (KROS) announced the acceptance of five abstracts for presentation at the 64th American Society of Hematology Annual Meeting, scheduled for December 10-13, 2022. The presentations include preliminary results from Phase 2 trials for KER-050, aimed at treating myelodysplastic syndromes and myelofibrosis, and KER-047 for iron-refractory iron deficiency anemia. CEO Jasbir S. Seehra highlighted this as an opportunity to share important updates and anticipates releasing additional efficacy data for KER-050 by mid-December.

Keros Therapeutics (KROS) reported a net loss of $23.5 million for Q3 2022, up from $20.3 million in Q3 2021, primarily due to increased R&D efforts. The company spent $21.0 million on R&D, a rise of $6.2 million year-over-year, while general administrative expenses also increased to $6.9 million. As of September 30, 2022, Keros held $239.4 million in cash, bolstered by recent share sales, ensuring funding into Q1 2025. The company is advancing its clinical programs and anticipates a Phase 2 trial for KER-012 in pulmonary arterial hypertension, with more data expected by year-end.

Keros Therapeutics (KROS) announced preliminary clinical data from the Part 2 multiple ascending dose portion of its Phase 1 trial of KER-012, presented at the American Society of Bone and Mineral Research annual meeting on September 11, 2022. The results indicate that KER-012 effectively inhibits activin signaling, evidenced by a 52% reduction in follicle-stimulating hormone levels and significant increases in bone-specific alkaline phosphatase markers. No clinically meaningful changes were noted in hemoglobin or red blood cells. Keros plans to initiate a Phase 2 trial for KER-012 in pulmonary arterial hypertension patients in early 2023.

Keros Therapeutics, Inc. (Nasdaq: KROS) announced participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 3:40 PM ET. CEO Jasbir S. Seehra, Ph.D., and CFO Keith Regnante will discuss the company's innovative treatments aimed at hematological, pulmonary, and musculoskeletal disorders. A live audio webcast will be available, and an archived replay can be accessed for 90 days on Keros' website. Keros focuses on developing therapies like KER-050, KER-047, and KER-012 for various medical needs.

Keros Therapeutics (Nasdaq: KROS) announced two abstracts from its KER-012 and KER-050 programs will be presented at the ASBMR 2022 Annual Meeting in Austin, Texas, from September 9-12, 2022. The oral presentation on KER-012 will discuss its tolerability and its potential bone anabolic effects, scheduled for September 11, 2022. Additionally, a poster presentation on KER-050 will cover its efficacy in improving bone loss in a mouse model of myelodysplastic syndrome, also on September 11, 2022.

Keros Therapeutics reported positive clinical data for KER-050 and KER-012, showcasing their potential in treating hematological disorders. In the Phase 2 study for KER-050, 44% of high transfusion burden patients achieved transfusion independence. KER-012 demonstrated favorable safety and biomarker improvements in healthy volunteers. Keros strengthened its cash position, extending its runway to Q3 2024. However, the company reported a net loss of $27.3 million for Q2 2022, up from $15.6 million in Q2 2021, attributed to increased R&D and infrastructure costs.

Keros Therapeutics, Inc. (Nasdaq: KROS) announced promising results from a preclinical study of RKER-012 for pulmonary arterial hypertension (PAH) at the Pulmonary Hypertension Association Conference (June 10-12, 2022). RKER-012, an Activin Receptor Type IIB ligand trap, significantly reduced cardiac and pulmonary pathology in a rodent model, leading to lower Fulton index and systolic pulmonary arterial pressure (sPAP) compared to the control. These results suggest RKER-012 could potentially mitigate PAH-related damage to the heart and lung tissues.

Keros Therapeutics (KROS) announced new data from its ongoing Phase 2 trial of KER-050, targeting myelodysplastic syndromes (MDS), presented at the EHA Congress. The trial showed 51.9% of evaluable patients achieved an overall erythroid response. Part 2 of the trial has begun with a starting dose of 3.75 mg/kg, allowing for escalation to 5.0 mg/kg. KER-050 displayed a favorable safety profile with no serious adverse events reported. Keros also shared preclinical findings on KER-050's potential effects on thrombopoiesis and anemia treatment, suggesting a strong basis for further development.